Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can more radiation beat lung cancer? new trial aims to find out

NCT ID NCT07015892

Disease control Sponsor: Instituto de Investigación Biomédica de Salamanca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether giving higher doses of radiation twice a day can improve outcomes for people with limited-stage small cell lung cancer. All 300 participants will receive standard chemotherapy and be randomly assigned to one of three radiation dose levels. The study will compare how long patients live without the cancer growing and overall survival, while also tracking side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy
What this could lead to
If successful, this could establish a more effective radiation dose for limited-stage small cell lung cancer, potentially improving long-term survival.
What could go wrong
This is a Phase 3 trial, but higher radiation doses may increase side effects. The benefit over standard treatment is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of small cell lung cancer (SCLC) * Limited-stage disease (Stage I-III; any T, any N, M0), eligible for definitive radiotherapy * Measurable disease according to RECIST 1.1 * Age ≥18 years * ECOG performance status 0-2 * No prior thoracic radiotherapy * Signed informed consent * Adequate hematologic function: WBC ≥3.0×10⁹/L, neutrophils ≥1.5×10⁹/L, platelets ≥100×10⁹/L, hemoglobin ≥90 g/L * Adequate liver and renal function: total bilirubin ≤1.5×ULN, AST/ALT ≤1.5×ULN, creatinine normal or CrCl ≥60 mL/min * Pulmonary function: FEV1 \>1 L or \>30% predicted; DLCO \>30% predicted Exclusion Criteria: * Prior surgery or radiotherapy for any lung cancer (SCLC or NSCLC) * Presence of malignant cells in pleural or pericardial effusion * Serious uncontrolled systemic disorders (e.g., active infection, unstable cardiovascular disease) * Medical, psychological, or social conditions that could interfere with compliance * Active malignancy other than SCLC (except localized prostate/breast cancer or basal cell carcinoma) * Refusal or inability to sign informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Small cell lung carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Small cell lung carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Complejo Asistencial Universitario de Salamanca

    RECRUITING

    Salamanca, Salamanca, 37007, Spain

  • Complejo Hospitalario Universitario de Santiago

    NOT_YET_RECRUITING

    Santiago de Compostela, Spain

  • Genesis Care

    NOT_YET_RECRUITING

    Seville, Spain

  • Hospital Dr. Negrin

    NOT_YET_RECRUITING

    Las Palmas de Gran Canaria, Spain

  • Hospital Gregorio Marañon

    NOT_YET_RECRUITING

    Madrid, Spain

  • Hospital La Fe

    NOT_YET_RECRUITING

    Valencia, Spain

  • Hospital Marques de Valdecilla

    NOT_YET_RECRUITING

    Santander, Spain

  • Hospital Ramon y Cajal

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Virgen de Arrixaca

    NOT_YET_RECRUITING

    Murcia, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, Spain

  • Hospital Universitario de Cruces

    NOT_YET_RECRUITING

    Barakaldo, Spain

  • Hospital Universitario de Torrecardenas

    NOT_YET_RECRUITING

    Almería, Spain

  • Instituto Catalán de Oncología

    NOT_YET_RECRUITING

    Girona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.